Ventricular tachycardia (VT) is an unpredictable and potentially deadly condition and should be promptly treated with catheter ablation and medication, before irreversible and potentially fatal organ damage follows. Unfortunately, this combination of treatments does not prevent VT reoccurrence in 30-50% of VT patients and while they can undergo multiple invasive ablations, technical difficulties or refusal of the patient can lead to a lack of effective treatment options. A promising novel, non-invasive treatment option for VT is stereotactic arrhythmia radioablation (STAR). Besides being non-invasive, STAR can also be used to reach locations that are inaccessible for catheter ablation, which may potentially improve effectiveness of overall VT treatment. Small scale first in men/early phase trials have been performed for STAR, providing proof-of-concept for clinical safety and efficacy. However, patients with recurrent VT are not a homogenous group and each center deals with different inclusion criteria, imaging and/or target definition. Many questions remain and the available studies lack the power to clinically validate the approach and prepare for late stage phase III trials. The STOPSTORM consortium sets out to consolidate all current and future European efforts to clinically validate STAR treatment by merging all data in a validation cohort study, standardising pre-treatment and follow-up, in order to collect the data sets and statistical power needed to unanimously establish clinical safety, efficacy and benefit for STAR. The STOPSTORM consortium also sets out to refine protocols and guidelines, determine volumes of interest, define and model the optimal target region and target dose, also in relation to surrounding healthy tissues (i.e. organs at risk) and determine which patient population and underlying cardiopathies respond best to STAR. By doing so the STOPSTORM consortium paves the way to consensus and future late stage clinical trials for STAR.

The consequences of SARS-CoV-2 exposure range from a lack of infection to lethal COVID-19. This immense inter-individual clinical variability is the key scientific and medical enigma in the field. While age and certain co-morbidities are known to influence disease outcome, these parameters do not explain all variation. In addition, there are other SARS-CoV-2 phenotypes of clinical importance: multisystem inflammatory syndrome in children and adults (MIS-C/A), and longCOVID. An important breakthrough to unravel the pathogenesis of COVID-19 came from our two Science papers that were recognized by Nature among the top 10 discoveries of 2020. We found that about 4% of patients with critical COVID-19 pneumonia had inborn errors of immunity (IEI) that impair TLR3- and IRF7-dependent type I interferon (IFN) immunity and at least 10% of the patients carried pre-existing autoantibodies (auto-Abs) neutralizing type I IFNs. These findings pave the way for further studies of COVID-19 pneumonia and other SARS-CoV-2 infection phenotypes and form the basis of the present research proposal, UNDINE, which follows a "bed side to bench" and "bench to bed side" approach, with the following objectivies i) to decipher the genetic and immunological basis of the various SARS-CoV-2 disease manifestations, to identify individuals at increased risk of critical COVID-19, post-infectious immunological complications, and vaccine failure iii) to develop ready-to-use diagnostic tests for large-scale detection of auto-Abs to type I IFNs and propose novel preventive and therapeutic approaches, based on the pathogenesis of SARS-CoV-2 infection for translation into personalised medicine. To achieve these goals, our project will coordinate a European multidisciplinary and translational research effort relying on a strong and synergistic combination of assets, including unique cohorts from 11 EU countries and state-of-the art human genetic, immunological and virological expertises and technologies.

See Far project aims to develop and validate a digitally enabled adaptive solution supporting ageing workforce with vision loss, an age-related condition, to remain actively involved in professional life, helping them to sustain and renew their work and personal life related skills and support independent active and healthy lifestyles. The See Far solution consists of two components: (i) See Far smart glasses where the display lenses are adapted to the needs of the users and optimize their view. In order this to be achieved a personalized visual assistant is developed capturing the condition of the eye, detecting the problem and provide the appropriate adjustment through the integration of augmented reality technologies. See Far smart glasses empower older adults to solve the most meaningful problems, transform how they design, build, maintain and collaborate in their organization, perceive the world conveniently and enjoy a safer exploration in an indoor/outdoor environment. (ii) See Far mobile application allowing monitoring of the central vision evolution and prediction of the risk for the presence of diseases (i.e. diabetes risk, cardiovascular risk). It will capture retinal images, through a digital direct ophthalmoscope attached in the smartphone, analyze the images (Image Analysis Component), and detect the type and the stage of vision impairment (Decision Support Component). The combination of the output of the See Far mobile application (indicator of the presence of a visual or not problem) with the output of the See Far smart glasses (type of daily visual issues the user has and his/her behavior) will lead to the provision of suggestions, through augmented reality, to the user supporting independent active and healthy lifestyles. The suggestions will be adaptive to the profile of the user through the Personalized visual recommendation service.

The public-private partnership, READI, seeks to help clinical studies (CS) to finally serve the complete general population, and therefore more patients. To date CS have struggled to recruit and retain participants from diverse backgrounds and communities, such as marginalized or disadvantaged groups (e.g., sexual, gender, age, cultural, and socioeconomic cohorts). The resulting knowledge gaps entrench or increase health disparities. The READI consortium strives to tackle these challenges by fostering a more cohesive and integrated CS ecosystem for underserved (US) and underrepresented (UR) communities. It will actively connect all key stakeholders who can facilitate access to a wide range of patient populations. It will provide these stakeholders with the necessary tools, training programs, and approaches essential for the recruitment and retention of US/UR patients in CS. In addition, it will design, build and implement a digital platform which is patient-centred, sustainable, open and innovative. This will foster improved access to CS information and READI tools, while also supporting patient connections with the created communities. Finally, at least 4 CS will be used for testing the effectiveness of the developed tools and approaches. READI has a three-fold objective: to help US/UR communities overcome CS participation barriers (e.g., lack of information/awareness, mistrust, poor communication, geographic limitations, prejudice), which in turn will improve research of many diseases and conditions, preventative care and treatment effectiveness in different demographic groups, and better serve society. READI’s success will draw from its interdisciplinary, multi-stakeholder, consortium composition of 73 organizations from 18 countries, with key expertise in drug development and CS (design and operations), engagement strategies for US/UR populations, digital platform development, training and capability building initiatives, effective communication and dissemination, long-term sustainability, ethics and regulatory affairs.

Efter sin uddannelse ved Kunstakademiet i Københan levede Bertel Thorvaldsen i Rom fra 1797 til 1838 (og 1841-1842). Gennem hele perioden samlede han på afstøbninger, ialt 657, som er bevarede i Thorvaldsens Museum. De er dels afstøbninger fra romerske kopier efter græske originaler, dels fra romerske originaler. Mange er små som 272 afstøbninger af hoveder fra Trajansøjlen i Rom. Nogle har at gøre med hans restaureringsopgaver som gavlgrupperne fra Aphaiatemplet på Ægina, som han udførte for Kronprins Ludvig af Bayern. Dette arbejde inspirerede ham til egne arbejder og det gælder for en lang række afstøbninger i hans samling, herunder mange af hans portrætter. Thorvaldsens samling blev katalogiseret i 1850, men er siden kun undtagelsesvist blevet inddraget i diskussionen om hans kunst og kilder til inspiration. I det foreliggende værk er der rådet bod herpå, og hele markedet for afstøbninger er grundigt analyseret: hvad kunne han erhverve, og hvad var vigtigt for ham at eje.